Opinion|Videos|November 19, 2026

Unmet Needs After Immunotherapy in Endometrial Cancer

Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute, and Bradley R. Corr, MD, of University of Colorado Cancer Center, identify the greatest unmet needs for patients with endometrial cancer who progress on immunotherapy, with moderator Shannon N. Westin, MD, MPH, FACOG, FASCO, of The University of Texas MD Anderson Cancer Center.

Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute, and Bradley R. Corr, MD, of University of Colorado Cancer Center, identify the greatest unmet needs for patients with endometrial cancer who progress on immunotherapy, with moderator Shannon N. Westin, MD, MPH, FACOG, FASCO, of The University of Texas MD Anderson Cancer Center. Secord says patients with mismatch repair proficient disease are most likely to progress and represent a tremendous unmet need, along with the subgroup of mismatch repair deficient patients who still progress. Corr says his institution prioritizes clinical trials of antibody-drug conjugates (ADCs) and expects these agents to become standard of care soon. Secord describes institutional and consortium data on adding lenvatinib to immunotherapy. Corr argues that ADC response rates are so strong that chemotherapy will be a low bar to beat, and Secord says she is ready for ADCs to replace platinum and taxane chemotherapy in the front line.

Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute, and Bradley R. Corr, MD, of University of Colorado Cancer Center, identify the greatest unmet needs for patients with endometrial cancer who progress on immunotherapy, with moderator Shannon N. Westin, MD, MPH, FACOG, FASCO, of The University of Texas MD Anderson Cancer Center. Secord says patients with mismatch repair proficient disease are most likely to progress and represent a tremendous unmet need, along with the subgroup of mismatch repair deficient patients who still progress. Corr says his institution prioritizes clinical trials of antibody-drug conjugates (ADCs) and expects these agents to become standard of care soon. Secord describes institutional and consortium data on adding lenvatinib to immunotherapy. Corr argues that ADC response rates are so strong that chemotherapy will be a low bar to beat, and Secord says she is ready for ADCs to replace platinum and taxane chemotherapy in the front line.


Related to this article